Olema Pharmaceuticals inc   (OLMA)
Other Ticker:  
Price: $12.3600 $-0.10 -0.803%
Day's High: $12.78 Week Perf: -8.85 %
Day's Low: $ 12.14 30 Day Perf: 25.48 %
Volume (M): 654 52 Wk High: $ 17.79
Volume (M$): $ 8,082 52 Wk Avg: $11.74
Open: $12.37 52 Wk Low: $7.68

 Market Capitalization (Millions $) 556
 Shares Outstanding (Millions) 45
 Employees 30
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -96
 Cash Flow (TTM) (Millions $) 91
 Capital Exp. (TTM) (Millions $) 0

Olema Pharmaceuticals Inc
Olema Pharmaceuticals Inc. is a clinical stage biopharmaceutical company that focuses on the development of novel cancer therapies. The company is headquartered in San Francisco, California and was founded in 201 Its mission is to develop innovative therapies that can improve the lives of patients who are suffering from cancer, by identifying and targeting cancer-specific vulnerabilities.

Olema's flagship drug candidate is known as OP-1250. It is a first-in-class small molecule that targets the estrogen receptor (ER) alpha and covalently binds to a cysteine residue to create a unique pharmacological profile that leads to sustained anti-tumor activity across multiple tumor types. The company believes that OP-1250 could become a superior estrogen receptor antagonist compared to existing drugs on the market, especially in breast cancer treatment.

Olema's research is based on the unique biology of cancer and how tumor cells grow and respond to different stimuli. The team at Olema is focused on developing targeted therapies that will be effective against specific types of cancers. In addition to its work on OP-1250, Olema is also developing other small molecule drugs simultaneously.

The CEO of Olema is Sean P. Bohen, M.D., Ph.D., who has over 20 years of experience in the pharmaceutical industry, including leadership roles at companies like AstraZeneca, Merck, and Genentech. He has assembled a strong team of experts in oncology drug development, clinical research, and regulatory affairs to help achieve Olema's goals.

As of August 2021, Olema Pharmaceuticals Inc. had a market capitalization of about $8 billion. The company has raised over $507 million in equity financing as well as receiving grants and awards from public and private entities.

In summary, Olema Pharmaceuticals Inc. is a clinical-stage company focused on developing targeted therapies for cancer treatment, with its leading drug candidate, OP-1250. The company has a strong management team, a solid research pipeline, and has received significant financial support from investors and from public and private grants. Olema is committed to bringing innovative therapies to patients living with cancer, making a difference in the world by improving treatments for cancer.

   Company Address: 780 Brannan Street San Francisco 94103
   Company Phone Number: 243-5555   Stock Exchange / Ticker: NASDAQ OLMA


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Stock Market Announcement

Olema Pharmaceuticals Continues to Expand Workforce through Stock Option Grants to New Employees

Published Tue, Jun 4 2024 8:28 PM UTC

Olema Pharmaceuticals, Inc., a renowned clinical-stage biopharmaceutical company dedicated to developing targeted therapies for women's cancers, has recently announced the granting of stock options to several new employees. These inducement grants aim to attract top talent and further strengthen the company's position in the market. With the aim of optimizing share...

Clinical Study

' Novel Combinatory Therapeutics in ER+/HER2- Metastatic Breast Cancer: Promising Data on Palazestrant with CDK4/6 Inhibitors

Published Wed, May 15 2024 11:01 AM UTC

'Abstract:' Olema Oncology (Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on developing targeted therapies for women's cancers, recently announced promising interim results from its ongoing Phase 1b/2 clinical studies. The studies involve the combination of palazestrant (OP-1250) with CDK4/6 inhibitors ribociclib and palbociclib in treating ER+/HER2- meta...

Clinical Study

Expanding Treatment Paradigms in Breast Cancer: An Exciting Development in Palazestrant and Ribociclib Combination Therapy

Published Wed, May 8 2024 11:02 AM UTC

Breast cancer remains a significant global health concern, affecting millions of women around the world. Significant advances have been made in the field of oncology, and targeted therapies have emerged as powerful tools in the fight against this relentless disease. In this article, we explore the ground-breaking clinical data presented by Olema Oncology at the 2024 ESMO Bre...


Olema Pharmaceuticals, Inc. Bolsters Workforce with Inducement Grants, Strengthening Commitment to Women's Oncology Advancements

Published Thu, May 2 2024 8:37 PM UTC

Olema Oncology Grants Inducement Options to New Employees, Enhancing Workforce and Driving Growth
San Francisco, May 02, 2024 - Olema Pharmaceuticals, Inc. (Nasdaq: OLMA), a clinical-stage biopharmaceutical company dedicated to developing targeted therapies for women's cancers, announced on May 1, 2024, that it has granted stock options to six new employees. Under the C...


Olema Pharmaceuticals Grants Stock Options to New Employees for Advancing Women's Cancer Therapies

Published Tue, Apr 2 2024 8:29 PM UTC

Olema Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing targeted therapies for women's cancers, recently announced the granting of stock options to two new employees. This move signifies the company's commitment to attracting top talent as it continues its efforts in the discovery, development, and commercialization of innovative tre...



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com